DEVONIAN HEALTH GROUP INC. TO PARTICIPATE IN THREE RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES.

QUEBEC, October 24, 2022 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today that they will be participating in three Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss the latest investor presentation.

Roadshow Series Event Full Schedule:
New York, USA: Tuesday, October 25, at 10:00 AM EDT
Boston, USA: Thursday, November 10, at 12:00 PM EDT
Toronto, Canada: Thursday, December 8, at 12:00 PM EDT.

The presentation will feature President & CEO Pierre Montanaro and Chief Scientific Officer Dr. André P. Boulet. Topics to be covered will include the latest corporate investor presentation followed by a live Q&A. Investors interested in participating in this event will need to register using the link below. As a reminder, registration for the live event may be limited, but access to the replay after the event will be on the company’s investor page (www.groupedevonian.com).

Devonian welcomes stakeholders, investors, and other individual followers to register and attend this live event.

REGISTER HERE:
New York City , Tuesday, October 25, 2022:
https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-tsx-v-gsd-otcqb-dvhgf-2022-10-25-100000

Boston, Thursday, November 10, 2022:
https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-tsx-v-gsd-otcqb-dvhgf-2022-11-10-120000

Toronto, Thursday, December 8, 2022:
https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-tsx-v-gsd-otcqb-dvhgf-2022-12-08-120000

• To ensure smooth connectivity, please access this link using the latest version of Google Chrome.  

About Devonian
Devonian Health Group Inc. (Devonian)is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian’s flagship product, Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with Mild-to-Moderate distal Ulcerative Colitis and in a large phase 2 clinical trial in adult patients with Mild-to-Moderate Atopic Dermatitis.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings.  Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Acquired in 2018, Altius Healthcare Inc., its commercialization subsidiary, brings opportunities for further diversification and growth potential. Devonian is listed on the TSX Venture Exchange (TSXV:GSD) as well as the OTCQB Venture Exchange (OTCQB:DVHGF)

For more information, visit www.groupedevonian.com

About Renmark Financial Communications Inc.
Founded in 1999, Renmark Financial Communications Inc. is North America’s leading retail investor relations firm.  Employing a strategic and comprehensive mix of exposure tactics; Renmark hosts Virtual Non-Deal Roadshows as well as in-person corporate presentations and maintains daily communications with thousands of brokers and money managers across Canada and the United States. Renmark empowers its publicly traded clientele to maximize their visibility within the financial community and strengthen their investor audience.

Renmark Financial Communications Inc.
Kerry Schacter: kschacter@renmarkfinancial.com
Tel.: (416) 644-2020 or (212) 812-7680
www.renmarkfinancial.com

The post DEVONIAN HEALTH GROUP INC. TO PARTICIPATE IN THREE RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES appeared first on DEVONIAN HEALTH GROUP INC..

DEVONIAN TO PRESENT THYKAMINE™ PHASE 2 CLINICAL RESULTS AT THE 6th DERMATOLOGY DRUG DEVELOPMENT SUMMIT FOR IINFLAMMATORY SKIN DISEASES.

QUEBEC, October 12, 2022 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today its presence at the upcoming 6^th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases (‘‘ADDDS’’) held on November 1-3, 2022, in Boston, MA, USA.

During this summit, the Corporation will present Thykamine™’s Phase 2 clinical trial results in Atopic dermatitis and other targeted skin inflammatory therapeutic applications.

Details of the Oral presentation are as follows:
Title: Thykamine™ A New Botanical Drug: A Serious Candidate for the treatment of Atopic dermatitis & Beyond.
Session: Emerging Clinical Candidates & Therapeutic Options
Date/Time: Thursday, November 3^rd , 2022, 13:40pm-14:10pm (EST)
Additional information, including the ADDDS full event guide, can be found at https://dermatology-drugdevelopment.com/

About Thykamine™
Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a phase II clinical study in patients with mild-to-moderate atopic dermatitis. Both Thykamine™ and SUPREX™ platform are protected by several patents in North America, Europe and Asia.

About Devonian
Devonian Health Group Inc. (Devonian)is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian’s flagship product, Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with Mild-to-Moderate distal Ulcerative Colitis and in a large phase 2 clinical trial in adult patients with Mild-to-Moderate Atopic Dermatitis.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings.  Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Acquired in 2018, Altius Healthcare Inc., its commercialization subsidiary, brings opportunities for further diversification and growth potential. Devonian is listed on the TSX Venture Exchange (TSXV:GSD) as well as the OTCQB Venture Exchange (OTCQB:DVHGF)

For more information, visit www.groupedevonian.com

Forward Looking Statements
This press release contains forward-looking statements about Devonian’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, the approval of the TSX Venture Exchange in connection with the issuance of the Units, Devonian’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian’s prospectus dated April 21^st, 2017, under the heading “Risk Factors” related to Devonian’s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact:
Dr. André P. Boulet, PhD
Chief Scientific Officer
Devonian Health Group Inc.
Telephone: (514) 248-7509
Email: apboulet@groupedevonian.com

The post DEVONIAN TO PRESENT THYKAMINE™ PHASE 2 CLINICAL RESULTS AT THE 6th DERMATOLOGY DRUG DEVELOPMENT SUMMIT FOR IINFLAMMATORY SKIN DISEASES appeared first on DEVONIAN HEALTH GROUP INC..

Devonian Health Group Announces Peer-reviewed publication of Thykamine™ positive phase 2 clinical trial results in Journal of Drugs in Dermatology.

• Clinical Study demonstrated dual benefit mode of action of Thykamine™ in mild-to-moderate Atopic Dermatitis:
  • Statistically significant effect on Atopic Dermatitis evaluated by measure of IGA, BSA and POEM
  • Statistically beneficial effect on Pruritis (‘‘itch’’)

QUEBEC, October 6, 2022 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD ; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, today announced the publication of Thykamine™ positive phase 2 trial in adult patients with mild-to-moderate Atopic Dermatitis (AD) in the peer-reviewed Journal of Drugs in Dermatology (JDD).

This article, titled ‘‘Phase 2 Trial of Topical Thykamine in Adults with Mild to Moderate Atopic Dermatitis’’ has been published in a JDD special issue focus on Atopic Dermatitis (J Drugs Dermatol 21(10): 1091-1097, October 2022).

The paper by Lynde et al. discloses the results of the Phase 2, multicenter, randomized, double-blind, placebo-controlled clinical trial conducted in 162 adult patients with mild-to-moderate AD. In this 4-week multicentre study, a significantly greater proportion of adult patients treated with Thykamine™ cream 0.10% achieved an IGA of clear/almost clear and at least a 2-grade improvement from baseline in IGA (30.8%) compared to placebo (6.7%; P =.014).  The benefit of Thykamine™ cream 0.10% was supported by a statistically significant effect on secondary endpoints of Body Surface Area (BSA), pruritis, and Patient-Oriented Eczema Measure score (POEM). A significant reduction in %BSA affected from baseline was demonstrated at all study visits. These changes differentiated significantly from placebo from Day 14 until Day 29 (p ≤ 0.001). Pruritus (‘‘itch’’) was rapidly improved from baseline by Day 7 with a statistically difference vs placebo at Day 21 and Day 29 (p ≤ 0.01). POEM outcome was statistically significant from placebo at day 21 and 29 (p ≤ 0.01).  Thykamine™, at all doses, was well tolerated with an adverse event profile like placebo.

‘‘We are proud to have our innovative Thykamine™ study results published in a reputable, peer-reviewed scientific journal,” said Dr André P. Boulet, PhD, Chief Scientific Officer of Devonian. ‘‘The efficacy of Thykamine™ obtained in this clinical trial compared favourably to published results of other therapeutic products such as the phosphodiesterase inhibitors (PDE4)^1,2 and calcineurin inhibitors.³ To our knowledge, it is the first time that clinical data revealed that a Botanical Drug candidate can be as potent as a product derived from chemical synthesis. Furthermore, the use of Thykamine™ was associated with a rapid improvement in itch in patients with mild to moderate AD. The fast onset of action and magnitude of itch relief associated with Thykamine™ cream treatment suggests that it may provide meaningful improvement in quality of life and addresses an unmet need for patients with AD,’’ added Dr Boulet.

About Atopic Dermatitis (AD)
AD, also known as eczema, is a type of inflammation of the skin. It results in itchy, red, swollen, and cracked skin that may lead to secondary infection. The condition typically starts in childhood with changing severity over the years. Although the cause of AD is unknown, it is believed to involve genetics, a compromised immune system and can be triggered by environmental factors. AD is the most common skin disease4 and its prevalence continues to increase worldwide. In the United States, the incidence has been reported to be 15-30% of children⁵. The severity of AD can be categorized into three stages, mild, moderate, and severe. The mild and moderate forms constitute approximately 67% and 26% respectively of the AD childhood patient population. A similar distribution has been reported in the adult patient population (71% and 26% respectively) ^6,7. There is currently an enormous unmet need for new, effective, and well-tolerated treatment options in AD⁸. Le marché mondial de la dermatite atopique devrait dépasser les US 21,8 milliards de dollars de ventes d’ici 2027⁹.

About Thykamine
Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a phase II clinical study in patients with mild-to-moderate atopic dermatitis. Both Thykamine™ and SUPREX™ platform are protected by several patents in North America, Europe and Asia.

About Devonian
Devonian Health Group Inc. (Devonian) is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian’s flagship product, Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with Mild-to-Moderate distal Ulcerative Colitis and in a large phase 2 clinical trial in adult patients with Mild-to-Moderate Atopic Dermatitis.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings.  Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Acquired in 2018, Altius Healthcare Inc., its commercialization subsidiary, brings opportunities for further diversification and growth potential. Devonian is listed on the TSX Venture Exchange (TSXV:GSD) as well as the OTCQB Venture Exchange (OTCQB:DVHGF)

For more information, visit www.groupedevonian.com

References

1. 1. Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesteras 4 (PDE4) inhibitors for the topical treatment of atopic dermatitis (AD) in children and adults. J. Am. Acad. Dermatol., Vol 75 (3), 494-503, 2016.
2. Hanifin JM., Ellis CN, Frieden IJ, et al. OPA-15406, a novel topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (A): A phase-II randomized, double-blind, placebo-controlled study. J Am Acad Dermatol, Vol 75 (2), 297-305, 2016.
3. Product Monograph, Elidel Cream 1%, Valeant Canada, 2014
4. Peng W., Novak N. Pathogenesis of atopic dermatitis. Clinical et Experimental Allergy 2015, 45 : 566-574.
5. Amy Huang, MD, Christine Cho, MD, Donald Y.M. Leung, MD, PhD, and Kanwaljit Brar, MD. Atopic Dermatitis: Early Treatment in Children. Curr Treat Options Allergy. 2017 Sep; 4(3): 355–369.
6. Silverberg JI, Simpson EL. Associations of childhood eczema severity: A US population-based study. Dermatitis 2014; 25(3):107-114.
7. Chaplin S. Guide to treatments used for atopic dermatitis in adults. Prescriber 2016: 27(10): 30-39.
8. Leung DYM. Guttman-Yassky E. Assessing the current treatment of atopic dermatitis: Unmet needs. J. of Allergy and Clinical Immunology. 2017; 139(4) Suppl.: S47-48.
9. Market Data Forecast, Global Atopic Dermatitis Treatment Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Treatment Type, Route Of Administration, Distribution Channel & Region – Industry Growth, Trends & Forecast (2021 to 2026), April 2021.

Forward-Looking Statements
This press release contains forward-looking statements about Devonian’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, the intended use of proceeds of the Offering, the final approval of the TSX Venture Exchange in connection with the Offering, the above “About Devonian” paragraph, Devonian’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian’s prospectus dated April 21^st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact:
Dr. André P. Boulet, PhD
Chief Scientific Officer
Devonian Health Group Inc.
Telephone: (514) 248-7509
e-mail: apboulet@groupedevonian.com

The post Devonian Health Group Announces Peer-reviewed publication of Thykamine™ positive phase 2 clinical trial results in Journal of Drugs in Dermatology appeared first on DEVONIAN HEALTH GROUP INC..

DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO DEBENTURE HOLDERS .

QUEBEC, September 7, 2022 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces the issuance of the following units in settlement of interests owed to holders of debentures issued in the private placement, as announced by press releases dated August 31, 2018:

• 87,840 units at a unit price of $0.40 (the “Units”) will be issued to holders of debentures issued in the second tranche of the private placement closed on August 31, 2018, in consideration for the interest due as of August 31, 2022, for a total amount of $35,136. Each Unit consists of one subordinate voting share of the Corporation (a “Subordinate Voting Share”) and one warrant (a “Warrant”). Each Warrant gives its holder the right to subscribe to a Subordinate Voting Share at a price of $0.52 for a period of 48 months.

The issuance of the Units is subject to the approval of the TSX Venture Exchange and will be subject to a hold period of 4 months and one day.

About Devonian
Devonian Health Group Inc. is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings.  Devonian Health Group Inc. was incorporated in 2013 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Acquired in 2018, Altius Healthcare Inc., its commercialization partner, brings opportunities for further diversification and growth potential.

Devonian is traded publicly on the TSX Venture Exchange (TSXv: GSD) and OTCQB Venture Exchange (OTCQB: DVHGF).

For more information, visit www.groupedevonian.com.

Forward Looking Statements
This press release contains forward-looking statements about Devonian’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, the approval of the TSX Venture Exchange in connection with the issuance of the Units, Devonian’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian’s prospectus dated April 21^st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact:
Dr. André P. Boulet, PhD
Chief Scientific Officer
Devonian Health Group Inc.
Telephone: (514) 909-3788
e-mail: apboulet@groupedevonian.com

The post DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO DEBENTURE HOLDERS appeared first on DEVONIAN HEALTH GROUP INC..

DEVONIAN ANNOUNCES EXECUTIVE CHANGES, GRANT OF STOCK OPTIONS AND SETTLEMENT OF INTERESTS AND REPAYMENT OF PRINCIPAL AMOUNT OWED TO A DEBENTURE HOLDER.

• Executive changes announced in support of the Corporation Growth Phase:
  • Ms. Sybil Dahan takes on the role of Devonian’s Chairperson of the Board of Directors
  • Mr. Pierre Montanaro takes on the role of Devonian’s President & CEO.
  • Dr André P. Boulet takes on the role of Chief Scientific Officer (CSO).
  • Restructuring of Devonian’s subsidiary Altius Healthcare Inc. (‘‘Altius’’):
    • Altius’ Board of Directors now composed of Messrs. Pierre Montanaro (Chairman), Denis Poirier and Guy Dancosse.
    • Mr. Pierre Montanaro takes on the role of Altius’ Chief Executive Officer.

QUEBEC, August 29, 2022 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today executive changes within Devonian and its subsidiary Altius Healthcare Inc. (‘‘Altius’’).

As Devonian is entering a new phase, the Corporation has decided to appoint Mr. Pierre Montanaro as President & Chief Executive Officer (‘‘CEO’’). This appointment further strengthens Devonian’s executive leadership team to drive its next phase of growth and operational success.  Dr André P. Boulet takes on the role of Chief Scientific Officer (‘‘CSO’’).

The corporation also announces that Ms. Sybil Dahan takes the role of Chairman of the Board of Directors.

‘‘As Devonian is entering a critical phase of its growth, we are taking thoughtful steps to further strengthen our executive leadership team” said Dr André P. Boulet.  ‘‘Ms. Dahan has been with us for more than 4 years. In her role as Chairman of the Board of Directors (the ‘‘Board’’), she will provide leadership in the management of the Board’s affairs and will ensure the Board fulfills its legislated mandate and responsibilities with full transparency and the application of sound governance practices. With respect to Mr. Pierre Montanaro, our new President & CEO, he has a long track record of success in large and mid-sized pharmaceutical companies covering brand and generic pharmaceuticals as well as over-the-counter products. His contribution will be invaluable in guiding Devonian through its next phase” added Dr Boulet.

“I feel very privileged to take on this role at such an exciting time at Devonian. I have worked alongside André for a few years now and have been impressed by Devonian’s resilience and dedication to the development of botanical drugs.” said Sybil Dahan. “This appointment brings with it the opportunity to further build on the work achieved to-date. As Devonian embarks on its next growth phase, I look forward to working with the board and management team as we forge a path to sustained success” added Sybil Dahan.

‘‘I am excited to join Devonian at this critical stage of its development’’ said Mr. Pierre Montanaro. ‘‘André and I have worked together in the past on a series of successful projects at Marion Merrell Dow.  Beginning in January 2022, I have assisted Dr. Boulet on several strategic projects related to Devonian namely financing activities, strategic planning, contract reviews and other initiatives linked to various business development projects in progress.  I am really looking forward to work with Dr Boulet and the team on staffing and restructuring the company for success while exploring partnership & licensing opportunities to maximize, for Devonian shareholders, the value of the company’s product pipeline with a clear focus on Thykamine™️ the company’s flagship product which shows enormous potential in Atopic Dermatitis and other inflammatory and immunomodulatory diseases’’ added Mr. Montanaro.

Executive changes within Altius Healthcare inc. (‘‘Altius’’)
The corporation has decided to make changes to Altius’ executive and Board of Directors. The corporation announces the appointment of Mr. Pierre Montanaro as CEO and Chairman of Altius’ Board of Directors (‘‘BOD’’). The BOD will also be composed of Messrs. Denis Poirier and Guy Dancosse.

About Pierre Montanaro
With a Bachelor of Commerce degree from Concordia University, Pierre has over 40 years of experience in the pharmaceutical and consumer product industries during which he has held various executive positions in marketing, sales and General Management.

Since December 2014, Pierre has been President of his own consulting firm TriumPharma Inc., which works with local and non-domestic clients to acquire and market pharmaceutical products in the Canadian marketplace. Previously, he held the position of President and Chief Executive Officer of Pharmetics, a company specializing in the development and sale of pharmaceutical and natural health products.

Before, Mr. Montanaro held various senior management positions for Pharmascience (2003-2011), Pharmacia (2001-2003), Marion Merrell Dow/Hoechst Marion Roussel/Aventis (1994-2001) and Burroughs Wellcome (1988-1994). During his long career in the pharmaceutical industry, Mr. Montanaro has always been recognized as a goal driven leader with an entrepreneurial spirit and a strong sense of urgency. His skills and multiple accomplishments earned him an induction into the Pharmaceutical Industry Marketing Hall of Fame in 2006.

Mr. Montanaro served for more than a decade on the Board of Directors of the Canadian Non-Prescription Drug Industry Association. In addition, he also sat on the board of directors of Collège Gérald Godin for more than three years.

Grant of Stock Options
In addition, the Company announces that the Board of Directors has approved the granting of options to purchase Shares (the “Options”). These Options are exercisable at a price of $0.50 for a period of five (5) years from the date of grant. A total of 50,000 Options have been granted to a director and 300,000 Options to employees of the Company. These Options are exercisable (‘‘Vested’’) on the grant date.

The Company has also granted, to Mr. Pierre Montanaro, 500,000 Options exercisable at the price of $0.50 for a period of ten (10) years. These options are vested according to the following schedule: 250,000 upon signature of the employment contract, and 250,000 on six months anniversary of the contract.

In addition, the Company has granted, to a consultant, 125,000 options exercisable at the price of $0.50 for a period of ten (10) years and all vested immediately.

Settlement of Interests and Repayment of Principal Amount of the Debenture of Aspri Pharma Canada Inc.
The Corporation announces the issuance of the following units in settlement of interests owed to Aspri Pharma Canada Inc. (“Aspri”), the holder of a 10% unsecured convertible debenture (the “Debenture”) issued in the first tranche of the private placement closed on July 19, 2018, as announced by the press release of the Corporation dated July 19, 2018:

• 93,564 units of the Corporation (the “Units”) at a price of $0.53 per Unit are issued in settlement of the interest due to Aspri as of July 19, 2022 (the “Maturity Date”), for a total amount of $49,589. Each Unit consists of one subordinate voting share of the Corporation (a “Share”) and one warrant of the Corporation (a “Warrant”). Each Warrant entitles its holder thereof to acquire a Share at a price of $0.69 for a period of 48 months following the date of issuance.

The issuance of the Units is subject to the approval of the TSX Venture Exchange and will be subject to a hold period of 4 months and one day.

The Corporation also announces the repayment, in favor of Aspri, of the principal amount of $1,000,000 of the Debenture, due as of the Maturity Date.

About Devonian
Devonian Health Group Inc. is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings.  Devonian Health Group Inc. was incorporated in 2013 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Acquired in 2018, Altius Healthcare Inc., its commercialization partner, brings opportunities for further diversification and growth potential.

Devonian is traded publicly on the TSX Venture Exchange (TSXv:GSD) and OTCQB Venture Exchange (OTCQB:DVHGF).

For more information, visit www.groupedevonian.com.

Forward Looking Statements
This press release contains forward-looking statements about Devonian’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, the approval of the TSX Venture Exchange in connection with the issuance of the Units, Devonian’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian’s prospectus dated April 21st, 2017, under the heading “Risk Factors” related to Devonian’s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact:
Dr. André P. Boulet, PhD
President, Chief Executive Officer
Devonian Health Group Inc.
Telephone: (514) 248-7509
e-mail: apboulet@groupedevonian.com

The post DEVONIAN ANNOUNCES EXECUTIVE CHANGES, GRANT OF STOCK OPTIONS AND SETTLEMENT OF INTERESTS AND REPAYMENT OF PRINCIPAL AMOUNT OWED TO A DEBENTURE HOLDER appeared first on DEVONIAN HEALTH GROUP INC..

Devonian Health Group Announces the Journal of Drugs in Dermatology acceptance for publication of Thykamine™ positive phase 2 clinical trial results in Atopic Dermatitis.

QUEBEC, May 26, 2022 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD ; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, today announced the acceptance for publication of results from its positive phase 2 trial of Thykamine™ in patients with mild-to-moderate Atopic Dermatitis (AD) in the peer-reviewed Journal of Drugs in Dermatology (JDD).

This JDD article, titled ‘‘Phase 2 Trial of Topical Thykamine™️ in Adults with Mild to Moderate Atopic Dermatitis’’ will be published in a special issue on Atopic Dermatitis planned for October 2022.

The Phase 2, multicenter, randomized, double-blind, placebo-controlled clinical trial was conducted in 162 patients with mild-to-moderate AD. In this 4-week, multicentre study, adult patients were randomized to receive Thykamine™ cream 0.05%, 0.10%, 0.25% or vehicle cream (placebo) twice daily. The primary efficacy endpoint was the Investigator Global Assessment (IGA) success rate defined as percentage of patients with an IGA score of 0 or 1 with greater than or equal to 2-grade reduction at week 4. Secondary endpoints included body surface area (BSA), pruritus and the Patient-Oriented Eczema Measure (POEM), among others.

The benefit of Thykamine™ cream 0.10% was supported by a statistically significant effect on the primary and secondary endpoints of Body Surface Area (BSA), pruritis, and Patient-Oriented Eczema Measure score (POEM).

“We are excited that Journal of Drugs in Dermatology has elected to publish, in a special issue on Atopic Dermatitis, the results of our Phase 2 study on Thykamine™️ which shows significant positive results posted by our product for the treatment of mild-to-moderate atopic dermatitis.  These positive results should validate the potential of Thykamine™️ in the armamentarium to treat this condition affecting millions of children and adults around the world” said Dr André P. Boulet, PhD, President and Chief Executive Officer of Devonian.  “The efficacy of Thykamine™ obtained in this Phase 2 clinical trial compared favourably to published results posted by other therapeutic products such as phosphodiesterase inhibitors ((PDE4)^1,2 and calcineurin inhibitors.³ To our knowledge, it is the first time that clinical trial data has demonstrated that a botanical drug candidate can be as potent as a product derived from chemical synthesis” added Dr. Boulet.

About Atopic Dermatitis (AD)

Atopic Dermatitis or eczema,is a chronic inflammatory disease of the skin that is recurrent. It is characterized by itchy, red, swollen and cracked skin that may lead to secondary infections. The condition typically starts in childhood with changing severity over the years. Although the cause of AD is unknown, it is believed to involve genetics, a compromised immune system and can be triggered by environmental factors. AD is the most common skin disease⁴ and its prevalence continues to increase worldwide. In the United States, the incidence has been reported to be 10-20% of children with new diagnoses at almost 11% per year⁵. The severity of AD can be categorized into three stages, mild, moderate, and severe. The mild and moderate forms constitute approximately 67% and 26% respectively of the AD childhood patient population. A similar distribution has been reported in the adult patient population (71% and 26% respectively) ^6,7. There is currently an enormous unmet need for new, effective, and well-tolerated treatment options in AD⁸. The global atopic dermatitis market is expected to exceed US $21,8 billion in sales by 2027⁹.

About Thykamine™
Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a phase II clinical study in patients with mild-to-moderate atopic dermatitis. Both Thykamine™ and SUPREX™ platform are protected by several patents in North America, Europe and Asia.

About Devonian
Devonian Health Group Inc. (Devonian) is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings.

Devonian is listed on the TSX Venture Exchange (TSXV:GSD) as well as the OTCQB Venture Exchange (OTCQB:DVHGF)

For more information, visit www.groupedevonian.com

References

1. Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesteras 4 (PDE4) inhibitors for the topical treatment of atopic dermatitis (AD) in children and adults. J. Am. Acad. Dermatol., Vol 75 (3), 494-503, 2016.
2. Hanifin JM., Ellis CN, Frieden IJ, et al. OPA-15406, a novel topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (A): A phase-II randomized, double-blind, placebo-controlled study. J Am Acad Dermatol, Vol 75 (2), 297-305, 2016.
3. Product Monograph, Elidel Cream 1%, Valeant Canada, 2014
4. Peng W., Novak N. Pathogenesis of atopic dermatitis. Clinical et Experimental Allergy 2015, 45 : 566-574.
5. Eichenfield F, Ellis CN, Mancini AJ, Paller AS, Simpsom EL. Atopic Dermatitis: Epidemiology and Pathogeneses Update. Semin Cutan Med Surg 2012, Sep; 31 (3 Suppl): S3-5.
6. Silverberg JI, Simpson EL. Associations of childhood eczema severity: A US population-based study. Dermatitis 2014; 25(3):107-114.
7. Chaplin S. Guide to treatments used for atopic dermatitis in adults. Prescriber 2016: 27(10): 30-39.
8. Leung DYM. Guttman-Yassky E. Assessing the current treatment of atopic dermatitis: Unmet needs. J. of Allergy and Clinical Immunology. 2017; 139(4) Suppl.: S47-48.
9. Market Data Forecast, Global Atopic Dermatitis Treatment Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Treatment Type, Route Of Administration, Distribution Channel & Region – Industry Growth, Trends & Forecast (2021 to 2026), April 2021.

Forward-Looking Statements
This press release contains forward-looking statements about Devonian’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, the intended use of proceeds of the Offering, the final approval of the TSX Venture Exchange in connection with the Offering, the above “About Devonian” paragraph, Devonian’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian’s prospectus dated April 21^st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact:
Dr. André P. Boulet, PhD
President, Chief Executive Officer
Devonian Health Group Inc.
Telephone: (514) 248-7509
e-mail: apboulet@groupedevonian.com

The post Devonian Health Group Announces the Journal of Drugs in Dermatology acceptance for publication of Thykamine™ positive phase 2 clinical trial results in Atopic Dermatitis appeared first on DEVONIAN HEALTH GROUP INC..

Devonian Announces Adoption of Restricted Share Unit Plan.

QUEBEC, March 17^th, 2022 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD ; OTCQB : DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce shareholder approval of a new restricted share unit plan (the “RSU Plan”).

RSU Plan
At the Corporation’s annual and special meeting of shareholders held on February 25, 2022 (the “Meeting”), the Corporation’s shareholders approved a resolution to adopt the RSU Plan.

Under the RSU Plan, restricted share units may be granted to directors, officers, employees and consultants of the Corporation or its affiliates. The aggregate number of subordinate voting shares of the Corporation (the “Shares”) that may be issued under the RSU Plan combined with all of the Corporation’s other security-based compensation mechanisms, including the Corporation’s stock option plan, shall not exceed 10% of the issued and outstanding Shares from time to time, which represents approximately 10,908,701 Shares on the date of approval of the RSU Plan. The RSU Plan remains subject to the TSX Venture Exchange (“TSXV Exchange”) approval.

Further details regarding the RSU Plan are included in the management proxy circular of the Corporation, which was filed on SEDAR in connection with the Meeting and available at www.sedar.com.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Devonian
Devonian Health Group Inc. is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian’s flagship product, Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with Mild-to-Moderate distal Ulcerative Colitis and in a large phase 2 clinical trial in adult patients with Mild-to-Moderate Atopic Dermatitis. The product is now ready to move into phase 3 clinical development.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Acquired in 2018, Altius Healthcare Inc., its commercialization subsidiary, brings opportunities for further diversification and growth potential. Devonian is traded publicly on the TSXV Exchange (TSXV:GSD) and on OTCQB exchange (OTCQB : DVHGF).

For more information, visit www.groupedevonian.com

Forward-Looking Statements
This press release contains forward-looking statements about Devonian’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, the TSXV Exchange final approval of the RSU Plan, the above “About Devonian” paragraph, Devonian’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian’s prospectus dated April 21^st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact:
Dr. André P. Boulet, PhD
President, Chief Executive Officer
Devonian Health Group Inc.
Telephone: (514) 248-7509
e-mail: apboulet@groupedevonian.com

The post Devonian Announces Adoption of Restricted Share Unit Plan appeared first on DEVONIAN HEALTH GROUP INC..

Devonian Health Group Announces trading on the OTCQB^® Market under symbol DVHGF.

QUEBEC, March 10, 2022 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that it has initiated quoting activity on the OTCQB® Venture Market (the “OTCQB“). Furthermore, Devonian has received the confirmation of its eligibility for settlement and transfer of its shares in the United States with The Depository Trust Company (“DTC“).

The Company’s common shares are quoted on the OTCQB under the symbol “DVHGF” and will continue to trade on the Toronto Stock Exchange Venture Market (‘‘TSXv’’) under the symbol “GSD”.

The OTCQB is the premiere marketplace for early stage and developing U.S. and international companies that are committed to providing a high-quality trading and information experience for their U.S. investors. To qualify for OTCQB, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. The OTCQB quality standards provide a strong baseline of transparency as well as the technology and regulation to improve the information and trading experience for investors. The OTCQB is recognized by the Securities and Exchange Commission as an established public market providing public information for analysis and value of securities. It is believed that being listed on the OTCQB would provide improved liquidity, an enhanced trading experience for current and potential U.S. investors and exposes the Company to a broader market.

DTC is a subsidiary of the Depository Trust & Clearing Corporation and manages the electronic clearing and settlement of publicly traded companies. DTC eligibility incorporates an electronic method of clearing securities that accelerates the receipt of stock and cash, reduces costs, and allows the stock to be traded over a much wider selection of brokerage firms by meeting their clearing and settlement requirements.

‘‘We are pleased to have initiated the quoting of our common shares on the OTCQB. This important step increases access to our shares to a wider range of institutional and retail investors in the United States. I am excited for these new investors to become familiar with the important scientific and clinical work we are doing to develop leading-edge botanical drugs. We continue to pursue advancements that will provide a large U.S. investor base with the opportunity to participate directly in our growth’’. said Dr André P. Boulet, PhD, President and Chief Executive Officer of Devonian. “Trading on OTCQB® will contribute to our strategy to continue to enhance our share liquidity and broaden the reach and awareness of our global pharmaceutical innovations and ultimately drive value for our shareholders.’’ Added Dr Boulet.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market for 11,000 U.S. and global securities. Through OTC Link® ATS and OTC Link ECN, the OTC connects a diverse network of broker-dealers that provide liquidity and execution services. The OTC Markets Group Inc. enables investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.

To learn more about the OTC Markets Group Inc., visit www.otcmarkets.com.

OTC Link ATS and OTC Link ECN are SEC regulated ATSs, operated by OTC Link LLC, member FINRA/SIPC.

About Devonian
Devonian Health Group Inc. is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian’s flagship product, Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with Mild-to-Moderate distal Ulcerative Colitis and in a large phase 2 clinical trial in adult patients with Mild-to-Moderate Atopic Dermatitis.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings.  Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Acquired in 2018, Altius Healthcare Inc., its commercialization subsidiary, brings opportunities for further diversification and growth potential.

For more information, visit www.groupedevonian.com

Forward-Looking Statements
This press release contains forward-looking statements about Devonian’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, the intended use of proceeds of the Offering, the final approval of the TSX Venture Exchange in connection with the Offering, the above “About Devonian” paragraph, Devonian’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian’s prospectus dated April 21^st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact:
Dr. André P. Boulet, PhD
President and Chief Executive Officer
Devonian Health Group Inc.
Telephone: (514) 248-7509
e-mail: apboulet@groupedevonian.com

The post Devonian Health Group Announces trading on the OTCQB® Market under symbol DVHGF appeared first on DEVONIAN HEALTH GROUP INC..

DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO DEBENTURE HOLDERS.

QUEBEC, March 7, 2022 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today the issuance of the following units in settlement of interests owed to holders of debentures issued in the private placement, as announced by a press release dated August 31, 2018:

• 73,540 units at a unit price of $0.47 (each, a “Unit”) will be issued to holders of debentures issued in the second tranche of the private placement closed on August 31, 2018, in consideration for the interest due on August 31, 2021 for an aggregate amount of $34,564. Each Unit consists of one subordinate voting share of the Corporation (a “Subordinate Voting Share”) and one warrant (a “Warrant”). Each Warrant entitles its holder to subscribe for one Subordinate Voting Share of the Corporation at a price of $0.61 for a period of 48 months.

The issuance of Units is subject to the approval of the TSX Venture Exchange and will be subject to a hold period of 4 months and one day.

About Devonian
Devonian Health Group Inc. is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian’s flagship product, Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with Mild-to-Moderate distal Ulcerative Colitis and in a large phase 2clinical trial in adult patients with Mild-to-Moderate Atopic Dermatitis.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings.  Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Acquired in 2018, Altius Healthcare Inc., its commercialization subsidiary, brings opportunities for further diversification and growth potential. Devonian is traded publicly on the TSXV Exchange (TSXv:GSD).

For more information, visit www.groupedevonian.com.

Forward Looking Statements
This press release contains forward-looking statements about Devonian’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, the approval of the TSX Venture Exchange in connection with the issuance of the Units, Devonian’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian’s prospectus dated April 21^st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact:
Dr. André P. Boulet, PhD
President and Chief Executive Officer
Devonian Health Group Inc.
Telephone: (514) 248-7509
e-mail: apboulet@groupedevonian.com

The post DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO DEBENTURE HOLDERS appeared first on DEVONIAN HEALTH GROUP INC..

Devonian Health Group Announces voting results of the Annual General and Special Meeting and welcome new board members.

QUEBEC,  – March 1^st , 2022 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today  the voting results of its Annual General and Special Meeting held on February 25, 2022 via videoconferencing.  The number of shares represented in person or by proxy represented 66.72 % of vote on all issued and outstanding shares of Devonian Health GroupInc.

Election of Directors
The nine (9) candidates nominated for election to the Devonian’s Board of Directors and listed in the Corporation’s Management Information Circular, dated January 26, 2022, were elected by a majority of the votes cast by shareholders present in person or represented by proxy at the meeting as follows:

Appointment of Auditors
In addition, Devonian announces today that 100% of its shareholders have approved the re-appointment of PricewaterhouseCoopers s.r.l/s.e.n.c.r.l  as the Auditor of the Corporation to hold office until the next annual meeting of shareholders.

Ratification and Confirmation of the Corporate’s Stock Option Plan
Devonian also announces today that 99.77 % of its shareholders have ratified and confirmed the Corporate’s Stock Option Plan.  

Ratification and Confirmation of the Corporate’s Restricted Share Unit Plan
Devonian also announces today that 93.85% of its shareholders have ratified and confirmed the Corporate’s Restricted Share Unit Plan.

Ratification of Shareholder Rights Plan
Devonian announces today that 99.97% of its shareholders have ratified and confirmed the Shareholder Rights Plan.

Issuance of subordinate voting shares
Devonian also announced today that 99.97% of its shareholders have approved the issuance of 1,311,553 subordinate voting shares at a price of $0.352 per subordinate voting share for a total amount of $461,666.74. to 9294-5039 Québec inc., a non-arm’s length firm with the Company. The subordinate voting shares are issued in settlement of a debt due for consulting services.

New Board Members
Devonian is pleased to announce the appointment of 2 new members to its Board of Directors. Joining the board are Denis Poirier and Pierre J. Montanaro. These appointments bring the Company’s total board membership to 9.

“We are excited to welcome these new independent directors to our Board,” said Dr André P. Boulet PhD, Devonian’s Chairman of the board. “They bring decades of expertise and leadership in key areas such as drug commercialization and strategic implementation. I am confident that they will provide valuable perspectives as we continue to execute our strategy of developing botanical drugs.”

Denis Poirier graduated from McGill University in 1978 with a bachelor’s in commerce and obtained a graduate diploma in accountancy in 1980 as well as the chartered accountant designation. From 1978 to 1996, Denis worked for two different accounting firms where he mainly practised in the areas of taxation and mergers and acquisitions. Denis joined the Royal Bank of Canada from 1996 to 1998 where after leading the $50 million first public offerings of Spectra Premium industries inc. he became their vice president taxation, financing and acquisitions and lead two additional public offerings in 1998 and 1999 for an additional $150 million. In 2007, Denis oversaw the privatization of Spectra Premium industries inc. and became its chief financial officer and one of its key shareholders until 2016 when he sold his shares. During his 18 years at Spectra Premium industries, Denis played a key role in the growth of the company where sales went from $30 million to more than $600 million and the headcount from 300 to more than 1,600 following more than 20 acquisitions in Canada, United States and Europe and following organic growth resulting from development of new products and new markets. Denis is well known for is deep knowledge and expertise in negotiation, taxation, business valuation, financing, acquisitions, business development and strategic planning.  Since 1998 Denis also acquired board of directors and advisory boards expertise among 8 publicly listed, private companies and non for profit organisations including la foundation des jeunes de la DPJ since 2009 where he is also the treasurer.

With a Bachelor of Commerce degree from Concordia University, Pierre Montanaro has over 40 years of experience in the pharmaceutical and consumer product industries during which he has held various executive positions in marketing, sales and General Management. Since December 2014, Pierre has been President of his own consulting firm TriumPharma Inc., which works with local and non-domestic clients to acquire and market pharmaceutical products in the Canadian marketplace.  Previously, he held the position of President and Chief Executive Officer of Pharmetics, a company specializing in the development and sale of pharmaceutical and natural health products.  Before, Mr. Montanaro held various senior management positions for Pharmascience (2003-2011), Pharmacia (2001-2003), Marion Merrell Dow/Hoechst Marion Roussel/Aventis (1994-2001) and Burroughs Wellcome (1988-1994). During his long career in the pharmaceutical industry, Mr. Montanaro has always been recognized as a goal driven leader with an entrepreneurial spirit and a strong sense of urgency. His skills and multiple accomplishments earned him an induction into the Pharmaceutical Industry Marketing Hall of Fame in 2006.

On a personal level, Mr. Montanaro served for more than a decade on the Board of Directors of the Canadian Non-Prescription Drug Industry Association. In addition, he also sat on the board of directors of Collège Gérald Godin for more than three years. Pierre Montanaro has been married to Danièle Lapierre for 45 years and is the father of two daughters, Sarah and Vanessa.

About Devonian
Devonian Health Group Inc. is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian’s flagship product, Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with Mild-to-Moderate distal Ulcerative Colitis and in a large phase 2 clinical trial in adult patients with Mild-to-Moderate Atopic Dermatitis. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Acquired in 2018, Altius Healthcare Inc., its commercialization subsidiary, brings opportunities for further diversification and growth potential. Devonian is traded publicly on the TSXV Exchange (TSXV:GSD).

For more information, visit www.groupedevonian.com

Forward Looking Statements
This press release contains forward-looking statements about Devonian’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Devonian’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian’s prospectus dated April 21^st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact:
Dr. André P. Boulet, PhD
President and Chief Executive Officer
Devonian Health Group Inc.
Telephone: (514) 248-7509
e-mail: apboulet@groupedevonian.com

The post Devonian Health Group Announces voting results of the Annual General and Special Meeting and welcome new board members appeared first on DEVONIAN HEALTH GROUP INC..